



OFFICE OF THE  
ASSISTANT SECRETARY FOR HEALTH

LEADING AMERICA TO HEALTHIER LIVES



ABBOTT BINAXNOW™ WEBINAR FOR  
ASSISTED LIVING FACILITIES

SEPTEMBER 18, 2020



# NOTICE

This webinar is intended for assisted living facilities receiving Abbott BinaxNOW™ tests from the U.S. Department of Health and Human Services.

It is not intended for members of the media.

# Agenda for today

---

Welcome

12:00 PM - 12:05 PM

Dr. Tammy Beckham, *Lead for Testing and Diagnostics Working Group at HHS*

Abbot BinaxNOW™ Overview

12:05 PM - 12:40 PM

Ashley Cilfone, *Director of Training and Development at Abbott*  
Amanda Simpson, *Director of Field Technical Operations at Abbott*  
David Kowalski, *Director of Global Marketing - Rapid Diagnostics*

CDC Update on Testing Guidance


12:40 PM - 12:50 PM

Dr. Nimalie Stone, *Long Term Care Team Lead at the CDC*

Q&A Session

12:50 PM - 1:00 PM

All panelists



**ABBOTT RAPID DIAGNOSTICS**

**BinaxNOW™ COVID-19 Ag Card Test  
& NAVICA™ App**

**HHS Assisted Living Webinar**

September 18, 2020

# Agenda

- Introduce Testing Solution
  - BinaxNOW™ COVID-19 Ag Card Test
  - NAVICA™ App
- Training Toolkit & Technical Resources
- Review FAQs

HHS ASSISTED LIVING WEBINAR

# BinaxNOW™ COVID-19 Ag Card Test Overview

# BinaxNOW™ COVID-19 AG CARD

## A Breakthrough Antigen Test

### SIMPLIFYING THE TEST PROCESS

- Cost-effective, high performing test designed for decentralized testing
- Simple test procedure
  - Direct Nasal swab
  - Onboard extraction allows the swab to be directly inserted into the test card
  - Visually read results in 15 minutes (no instrument required)
- Emergency Use Authorization (EUA) supports testing in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance or Certificate of Accreditation\*

#### PERFORMANCE

Sensitivity (PPA) **97.1%**

Specificity (NPA) **98.5%**

Direct nasal swabs from individuals suspected of COVID-19 by their healthcare provider within the first seven days of symptom onset.



# Intended Use

## Key Points

- The BinaxNOW™ COVID-19 Ag Card is intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in nasal swabs from **individuals suspected of COVID-19 by their healthcare provider within the first seven days of symptom onset.**
- Antigen is generally detectable in nasal swabs during the **acute phase of infection.**
- Negative results from patients with symptom onset beyond seven days, should be treated as presumptive and confirmation with a molecular assay if necessary, for patient management, may be performed



# Intended Use

## Resources for Questions

### **Resources for Intended Use Questions:**

- For FDA recommendations for Health Care Providers who are ordering tests outside of their authorization (e.g. antigen tests for asymptomatic individuals) – [see FDA's FAQ on Testing for SARS-CoV-2](#)
- [Refer to the PREP Act Coverage for COVID-19 Screening at Congregate Facilities document](#) - for Guidance from the Department of Health and Human Services
- Direct any additional questions regarding BinaxNOW Ag Card Intended Use to the Abbott Technical Services Team at 1-800-257-9525 between 8 a.m. and 8 p.m. EST Monday-Friday or email [ts.scr@abbott.com](mailto:ts.scr@abbott.com)

# BinaxNOW™ COVID-19 Ag

## *Emergency Use Authorization*

The BinaxNOW COVID-19 Ag Card is only for use under the Food and Drug Administration's Emergency Use Authorization

### **What is Emergency Use Authorization (EUA)?**

- FDA emergency access mechanism
- Health & Human Services declare when circumstances exist to justify use of diagnostics under EUA for the diagnosis of COVID-19
- It is not full FDA clearance or approval and is temporary, until the declaration is terminated or revoked.

# BinaxNOW™ COVID-19 Ag

## *Emergency Use Authorization Responsibility*

### **Test Site Obligations:**

- Notify relevant public health authorities on intent to run test
- Report all results to healthcare providers and include the Healthcare Provider Fact Sheet. Healthcare providers to include Patient Fact Sheet with results
- Ensure all operators are trained to perform and interpret the test
- Per Product Insert: Collect performance data and report via email to FDA/HHS and to Abbott Technical Support
- Retain all records associated with EUA until otherwise directed by FDA

HHS ASSISTED LIVING WEBINAR

# BinaxNOW™ COVID-19 Ag Card Technical Overview

# BinaxNOW™ COVID-19 Ag Card

## Product Overview

<b>Test Summary</b>	Rapid lateral flow immunoassay for the qualitative detection and diagnosis of SARS-CoV-2
<b>Testing Environment</b>	Point of Care settings with a CLIA Certificate of Waiver
<b>Specimen Type</b>	Direct nasal swab
<b>Time to Result</b>	Results visually read at 15 minutes *Results should not be read after 30 minutes
<b>Reagent &amp; Materials</b>	40 test cards, extraction reagent, QC & patient collection swabs, Product Insert, Procedure Card & Fact Sheets
<b>Waste Disposal</b>	All components should be discarded as Biohazard Waste
<b>PPE for Specimen Collection and Handling</b>	Refer to CDC Guidelines for collecting, handling and testing clinical specimens (link in Product Insert)

# Internal Quality Control

## Internal Procedural Controls:

- BinaxNOW™ COVID-19 Ag Card has built-in procedural controls
- In an untested card there will be a blue line at the Control Line position
- In a valid, tested device, the blue line washes away and a pink/purple line appears, confirming that the sample has flowed through the test strip and the reagents are working



*Note: If the blue line is not present at the Control Line position prior to running the test, do not use and discard*

# When is Quality Control Required?

## External Positive & Negative Controls:

- Good laboratory practice suggests the use of positive and negative controls to ensure that test reagents are working properly and that the test is correctly performed
- BinaxNOW™ COVID-19 Ag Card kits contain a positive control swab and sterile swabs that can be used as a negative control

## Required Frequency:

- New shipments received
- Untrained operators
- Conforming with local, state, and/or federal regulations, accrediting groups, or lab's standard QC procedures.




**Note:** If correct results are not obtained, contact the Abbott Technical Services Team at 1-800-257-9525 between 8 a.m. and 8 p.m. EST Monday-Friday before testing patient specimens

# Nasal Swab Sample Collection

## Sample Collection Key Points:

- **Only the swab provided in the kit is to be used for nasal swab collection**
- Insert swab until resistance is met
  - At the level of the nasal turbinates
  - less than 1 inch into the nostril
- Rotate the swab **5 times** or more against the nasal wall
- Using the same swab, **repeat sample collection in the other nostril**



1 To collect a nasal swab sample, carefully insert the swab into the nostril exhibiting the most visible drainage, or the nostril that is most congested if drainage is not visible.







2 Using gentle rotation, push the swab until resistance is met at the level of the turbinates (less than one inch into the nostril). Rotate the swab 5 times or more against the nasal wall and then slowly remove from the nostril.

3 Using the same swab, repeat sample collection in the other nostril.

For optimal performance, test specimens immediately after collection



# BinaxNOW™ COVID-19 Ag Card Test Procedure Overview



- To ensure proper test performance read results at **15 minutes** and not before
- Results should not be read after 30mins

# Additional Resources

## **Ordering Information**

- 195-000: BinaxNOW™ COVID-19 Ag Card (40 Tests)
- 195-080: BinaxNOW™ COVID-19 Ag Control Swab Kit (10 positive swabs)
- 190-010: Optional COVID-19 Swab Transport Tube Accessory Pack (24 tubes)

## **Technical Support Line:**

- US +1 800 257 9525, 8am-8pm EST M-F
- [ts.scr@abbott.com](mailto:ts.scr@abbott.com)

HHS ASSISTED LIVING WEBINAR

# NAVICA<sup>TM</sup> App

# Introducing NAVICA.

An end-to-end, secure, accessible COVID-19 Testing Solution



**A digital COVID-19 application designed to create a personalized and seamless testing experience that is available to all**

# NAVICA™ Has a Familiar Experience to Apps We Use Everyday

## **Simplicity**

- Based on familiar consumer experiences
- Low learning required to setup and use without help
- Designed to scale rapidly

## **Availability**

- Available on App Store and Google Play Store




## **Security**

- Cloud based, scalable infrastructure with independent ongoing security assessments to maintain the security of the platform
- Data is fully encrypted at all times.



NAVICA


# Downloading and sign-up is quick, simple, and secure






NAVICA


# NAVICA™ App for Test Participants BinaxNOW™ COVID-19 Test Results Quickly and Securely Shared




**Find Testing Sites**



**Use NAVICA ID  
To Get Tested**



**Receive Test Results  
Electronically**




**Use NAVICA Pass  
To Show Status**






NAVICA

# NAVICA™ Verifier

## Verification of an Authentic and Secure NAVICA Pass



NAVICA Pass




Status Can Be Confirmed Using NAVICA Verifier Available in NAVICA Application






# NAVICA Administrator guides the test operator through the process of capturing the test result\*




### Ease of Use

- Intuitive Design
- Simple Log in Process
- Focus on Patient/Participant




### Workflow Confirmations

- App guides admin through process
- Verify NAVICA ID with Photo ID



### Accurate and Secure.

- Connects NAVICA ID with BinaxNOW COVID-19 test card




### Connected and Private

- NAVICA ID and test card connection confirmed by rescanning test card
- Results visually interpreted and then securely communicated to NAVICA test participant


\*NAVICA Administrator app is designed be used with an Apple or Android tablet




# NAVICA™ Administrator Verify Test is Authentic, Unused, and Will be Matched to the Participant





**Intuitive workflow for reporting results digitally**



**Scan the test to securely retrieve the right test record**



**Tap to report the results to the participant electronically**



**Automatically updates NAVICA participant**

NAVICA APP AND BINAXNOW COVID-19 AG CARD

# Training Toolkit

# Training Toolkit Homepage

## Step 1:

### BinaxNOW® COVID-19 Ag Card Demo Video

The BinaxNOW demo video provides an overview of the BinaxNOW test process. This video can be viewed prior to the more detailed training to see a brief demonstration of the testing process from start to finish.

The screenshot shows the training toolkit homepage for the BinaxNOW COVID-19 Ag Card and NAVICA™ app. The page is titled "BINAXNOW™ COVID-19 AG CARD AND NAVICA™ APP SET-UP AND TRAINING" and includes a welcome message, introductory text, and a list of training materials. A navigation menu on the right side of the page lists the following items:

- BINAXNOW COVID-19 AG CARD OVERVIEW
- MODULE 1: GETTING STARTED
- MODULE 2: QUALITY CONTROL
- MODULE 3: SPECIMEN COLLECTION AND HANDLING
- MODULE 4: PATIENT INDIVIDUAL TEST

Below the navigation menu, there are several expandable sections:

- NAVICA™ CONSUMER DEMONSTRATION VIDEO
- HELPFUL DOCUMENTS
- BINAXNOW™ COVID-19 AG CARD FREQUENTLY ASKED QUESTIONS
- SUPPORT CONTACTS
- REFERENCES

At the bottom of the page, there is a section titled "NAVICA™ MOBILE APP AND BINAXNOW™ COVID-19 AG CARD" with a small image of the app and card.

# Training Toolkit Homepage

## Step 2:

### BinaxNOW® COVID-19 Ag Card Training Videos

The BinaxNOW training video provides a detailed step by step guide to the BinaxNOW test process. The training video, divided into modules, should be completed in its entirety before performing tests on individuals.

- Module 1: Getting Started
- Module 2: Quality Control
- Module 3: Specimen Collection & Handling
- Module 4: Patient Test

The screenshot shows the training toolkit homepage for the BinaxNOW COVID-19 Ag Card and NAVICA™ App. The page is titled "BINAXNOW™ COVID-19 AG CARD AND NAVICA™ APP SET-UP AND TRAINING" and includes a welcome message, introductory text, and a list of training materials. A prominent feature is a video player for the "BINAXNOW COVID-19 AG CARD OVERVIEW" video, which is divided into four modules: Module 1: Getting Started, Module 2: Quality Control, Module 3: Specimen Collection and Handling, and Module 4: Patient Individual Test. Below the video player, there are links to "NAVICA™ CONSUMER DEMONSTRATION VIDEO", "HELPFUL DOCUMENTS", "BINAXNOW™ COVID-19 AG CARD FREQUENTLY ASKED QUESTIONS", "SUPPORT CONTACTS", and "REFERENCES".

# Training Toolkit Homepage

## Step 3:

### Review Support Documents & Contacts

- NAVICA™ Demonstration Video
- BinaxNOW® COVID-19 Ag Card Training Document
- Product Insert
- Procedure Cards
- Clinical and Laboratory Standards Institute (CLSI) Documents
- Introduction to CLIA-Waived Testing
- Support Contacts: Technical Service Phone and Email
- FAQs

The screenshot shows the Abbott Training Toolkit homepage. At the top, the Abbott logo and navigation links are visible. The main heading is "BINAXNOW™ COVID-19 AG CARD AND NAVICA™ APP SET-UP AND TRAINING". Below this, there is a welcome message and introductory text. A central image shows the NAVICA app on a smartphone and the BinaxNOW COVID-19 Ag Card. The page is organized into sections: "BINAXNOW™ COVID-19 AG CARD AND NAVICA™ TRAINING MATERIALS", "OVERVIEW & TRAINING VIDEOS", and "BINAXNOW COVID-19 AG CARD OVERVIEW". The "OVERVIEW & TRAINING VIDEOS" section includes a list of modules: "MODULE 1: GETTING STARTED", "MODULE 2: QUALITY CONTROL", "MODULE 3: SPECIMEN COLLECTION AND HANDLING", and "MODULE 4: PATIENT INDIVIDUAL TEST". Below this, there are expandable sections for "NAVICA™ CONSUMER DEMONSTRATION VIDEO", "HELPFUL DOCUMENTS", "BINAXNOW™ COVID-19 AG CARD FREQUENTLY ASKED QUESTIONS", "SUPPORT CONTACTS", and "REFERENCES". At the bottom, there is a section for "NAVICA™ MOBILE APP AND BINAXNOW™ COVID-19 AG CARD" with a brief description of the app and card.

# Technical Services

For any questions pertaining to the BinaxNOW COVID-19 Ag Card or NAVICA, please contact the Abbott Technical Services Team

---

1-800-257-9525 between 8 a.m and 8 p.m. EST Monday-Friday  
Email [ts.scr@abbott.com](mailto:ts.scr@abbott.com).




**Abbott**



# Detecting/Responding to SARS-CoV-2: Considerations for Assisted Living/ Residential Care Facilities

Nimalie D. Stone, MD  
Long-term Care Team Lead



For more information: [www.cdc.gov/COVID19](https://www.cdc.gov/COVID19)

## Coronavirus Disease 2019 (COVID-19)



- Your Health
- Community, Work & School
- Healthcare Workers & Labs**
- Health Depts
- Cases & Data
- More

### Healthcare Workers

- Testing
- Clinical Care
- Infection Control**
- Infection Control Guidance
- Using PPE
- Hand Hygiene
- Alternate Care Sites
- Assisted Living Facilities**
- Blood & Plasma Facilities
- Dental Settings
- Dialysis Facilities
- Nursing Homes & Long-Term Care Facilities
- Pharmacies
- Postmortem Guidance
- Optimize PPE Supply
- Potential Exposure at Work
- First Responder Guidance

### HEALTHCARE WORKERS

## Considerations for Preventing Spread of COVID-19 in Assisted Living Facilities

Updated May 29, 2020

[Print](#)



### Summary of Changes to the Guidance:

#### Below are changes to the guidance as of May 29, 2020:

- Updated recommendations about visitor restrictions and group activities to assist facilities if, based on guidance from their state and local officials, they begin to relax restrictions
- Added information about the [National Healthcare Safety Network \(NHSN\) Long-term Care Facility \(LTCF\) COVID-19 module](#), which can assist with tracking infections and prevention process measures in a systematic way.

### Key Actions

- Assisted living facility (ALF) owners and administrators should refer to guidance from state and local officials when making decisions about relaxing restrictions (e.g., easing visitor restrictions, allowing group activities, or restoring communal dining)
- State licensing authorities, which have oversight of ALFs, are encouraged to share this guidance with all ALFs in their jurisdiction. [State healthcare-associated infections programs](#) are an important resource to assist ALFs with responding to COVID-19 and implementing recommended practices.

Given their congregate nature and population served, assisted living facilities (ALFs) are at high risk for SARS-CoV-2 spreading among their residents. If infected with SARS-CoV-2, the virus that causes COVID-19, assisted living residents—often older adults with underlying medical conditions—are at [increased risk](#) for severe illness. CDC is aware of confirmed cases of COVID-19 among residents of ALFs in multiple states. [Experience with outbreaks in nursing homes](#) has demonstrated that **residents with COVID-19 may not report common symptoms such as fever or respiratory symptoms;**

<https://www.cdc.gov/coronavirus/2019-ncov/hcp/assisted-living.html>



# Core Activities: Maintaining COVID-19 Readiness

- Identify a point of contact at the local health department to facilitate prompt notification
- Educate residents, family members, and personnel about COVID-19
- Have a plan for visitor and personnel restrictions
- Encourage source control / Encourage social (physical) distancing
- Provide access to supplies and implement recommended infection prevention and control practices
- Rapidly identify and properly respond to residents with suspected or confirmed COVID-19
- Report COVID-19 cases, facility staffing, and supply information to the [National Healthcare Safety Network \(NHSN\) Long-term Care Facility \(LTCF\) COVID-19 module](#) (optional surveillance resource)



# Core Activities: Maintain Supplies to Implement IPC

- **Access to hand hygiene** – using alcohol-based hand sanitizer to make it easier to incorporate hand hygiene into workflow and during high risk activities (e.g., PPE doffing)
- **Use of appropriate products for cleaning and disinfection** of shared equipment and environmental surfaces
- **Personal protective equipment (PPE)**
  - Continuing to monitor PPE use (burn-rate) and maintain supplies
  - Ensure ongoing familiarity with PPE equipment selection and handling, especially if supplies change
  - Resources on PPE selection/use and conservation strategies
    - <https://www.cdc.gov/coronavirus/2019-ncov/hcp/using-ppe.html>
    - <https://www.cdc.gov/coronavirus/2019-ncov/hcp/ppe-strategy/index.html>




# SARS-CoV-2 Testing Considerations



# COVID-19 Infection Timeline and Testing

Figure. Estimated Variation Over Time in Diagnostic Tests for Detection of SARS-CoV-2 Infection Relative to Symptom Onset



# Understanding SARS-CoV-2 tests

Table 2. Comparison of In Vitro SARS-CoV-2 Tests Granted Emergency Use Authorizations by the U.S. FDA

	Molecular	Antigen	Serology
Test Type	Viral	Viral	Antibody
Diagnostic Test	Yes	Yes	No
Description	Nucleic acid amplification test to detect viral RNA	Detects viral proteins in the nasal cavity	Detects the presence of IgA, IgM & IgG antibodies against SARS-CoV-2
Measure	Current infection with SARS-CoV-2	Current infection with SARS-CoV-2	Past exposure to SARS-CoV-2
Platform Technology	RT-PCR, LAMP, CRISPR	Lateral Flow	Lateral Flow, ELISA, CIA
Sample Type	Nasal or throat swab, Saliva, Bronchoalveolar lavage fluid	Nasal or throat swab	Blood draw (plasma, serum, whole blood) or Finger Stick
Testing Window	Days 1-28 after symptom onset, Optimal days 3-12	Days 1-28 after symptom onset, Optimal days 3-12	IgA/IgM: From day 5 after symptom onset, Optimal days 14-21; IgG: From day 14 after symptom onset up to 6 weeks
Result Turnaround Time	Same day or up to a week (depending on location); Point-of-care option available (within 1-2 hours)	Rapid, point-of-care (within 15 minutes)	Same day or up to 1-3 days (depending on location); Point-of-care option available (within 15-30 minutes)

- Only viral diagnostic tests (molecular “PCR” or antigen) can be used to determine presence of active COVID-19 infection
- Serology, or “antibody” testing is used to determine previous infection



Chau CH et al. *Pharmacotherapy* 2020 Jul 8;10.1002/phar.2439. doi: 10.1002/phar.2439  
<https://www.cdc.gov/coronavirus/2019-ncov/hcp/faq.html>

# Factors that can impact test results

- Quality of the specimen collection
  - Inadequate sampling or mishandling of the specimen prior to running the diagnostic test can impact detection
- Proper use of the testing platform
  - Personnel should be trained and proficient in sample handling and running the tests
  - Use of positive and negative quality controls
- Clinical presentation at the time of the test (e.g., recent exposure or symptoms)
- Prevalence of COVID-19 in the center and community






# SARS-CoV-2 Testing in Response to a Case

- A new SARS-CoV-2 infection in any healthcare personnel (HCP) or any facility-onset SARS-CoV-2 infection in a resident should prompt investigation
- Expand diagnostic testing for all residents and healthcare personnel
  - Prioritize symptomatic residents and healthcare personnel
  - If testing supplies or capacity is limited, perform unit-based testing or testing other high-risk residents (e.g., roommates of COVID-19 infected residents)
- Perform repeat testing of all previously negative residents and HCP
  - Testing should be performed every 3-7 days until no new positive results are found for at least 14 days since last positive test result
  - If testing capacity is limited, prioritize testing for residents with known exposure to a case, residents and HCP on affected units



# Considerations for interpreting antigen testing results

- New CDC guidance to support use of point of care antigen tests



<https://www.cdc.gov/coronavirus/2019-ncov/hcp/nursing-homes-antigen-testing.html>




- Home Healthcare Workers
- Testing +
- Clinical Care +
- Infection Control -**
  - Infection Control Guidance
  - Using PPE
  - Hand Hygiene
  - Alternate Care Sites
  - Assisted Living Facilities
  - Blood & Plasma Facilities
  - Dental Settings
  - Dialysis Facilities +
  - Nursing Homes & Long-Term Care Facilities -**
    - Infection Control for Nursing Homes
    - Responding to COVID-19
    - Testing Residents
    - Testing Facility-Wide
    - Memory Care Units
    - Infection Control Assessment Tool
  - Pharmacies
  - Postmortem Guidance
- Optimize PPE Supply +
- Potential Exposure at Work +
- First Responder Guidance

HEALTHCARE WORKERS

## Nursing Homes and Long-Term Care Facilities

Updated Aug. 24, 2020

Print



### Infection Control Guidance

[Infection Control for Nursing Homes](#)

[Public Health Response in Nursing Homes](#)

[Infection Control in Memory Care Units](#)

[Infection Control FAQs](#)

### SARS-CoV-2 Testing Guidance

[Testing Nursing Home Residents](#)

[Testing Healthcare Personnel](#)

[Facility-wide Testing in Nursing Homes](#)

[Testing FAQs](#)

### Infection Control Assessment Tool

[Nursing Home COVID-19 Infection Control Assessment and Response \(ICAR\) Tool](#)

Tool to help nursing homes and assisted living facilities develop a comprehensive COVID-19 response plan.

### Training Resources

[Applying COVID-19 Infection Control Strategies in Nursing Homes](#)

Clinical Outreach and Communication Activity (COCA) Webinar, June 16, 2020.

Case-based scenarios are used to discuss how to apply infection prevention and control guidance for nursing homes and other long-term care facilities preparing for and responding to COVID-19.

[Nursing Home Infection Preventionist Training Course \(CDC TRAIN\)](#)

CDC TRAIN course, a free service from the Public Health Foundation

### Videos for Training Front Line Long-Term Care Staff




Mini Webinar training series for front-line staff to help protect residents from COVID-19

• [Keep COVID-19 Out](#)

- CDC COVID-19 Resource Page
  - Infection Control Guidance
  - Testing guidance
  - Assessment tools
  - Training materials



<https://www.cdc.gov/coronavirus/2019-ncov/hcp/nursing-home-long-term-care.html>



For more information, contact CDC  
1-800-CDC-INFO (232-4636)  
TTY: 1-888-232-6348 [www.cdc.gov](http://www.cdc.gov)

# Thank you!

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.



# Q&A

To ask a question of the panelists, please submit your question through the Zoom **Q&A Chat Box**



For further questions, please contact Abbott at [ts.scr@abbott.com](mailto:ts.scr@abbott.com).



## Retail pharmacy contacts



Ryan Koo: [KooR@cvshealth.com](mailto:KooR@cvshealth.com)

Emmanuel Kolady: [Emmanuel.Kolady@cvshealth.com](mailto:Emmanuel.Kolady@cvshealth.com)

Leanne Gassaway: [Leanne.Gassaway@cvshealth.com](mailto:Leanne.Gassaway@cvshealth.com)

---



Amanda Jenkins: [Amanda.Jenkins@Walmart.com](mailto:Amanda.Jenkins@Walmart.com)

---



Casey Cesnovar: [casey.cesnovar@walgreens.com](mailto:casey.cesnovar@walgreens.com)

## Other pharmacy partners



Troy Trygstad: [ttrygstad@cpesn.com](mailto:ttrygstad@cpesn.com)

CPESN Local Network Contact Information:

<https://www.cpesn.com/media/1200/cpesn-usa-local-network-contact-information.pdf>

---



Nancy Lyons: [Nancy.Lyons@McKesson.com](mailto:Nancy.Lyons@McKesson.com)

---



Jennifer Zilka: [jzilka@amerisourcebergen.com](mailto:jzilka@amerisourcebergen.com)

For additional questions to our presenters, please reach out directly

Abbott  
BinaxNOW™  
technical  
assistance

[ts.scr@abbott.com.](mailto:ts.scr@abbott.com)

Abbott  
BinaxNOW™  
shipment  
assistance

[ARDxUSGovernmentSupport@abbott.com.](mailto:ARDxUSGovernmentSupport@abbott.com)

CDC

<https://www.cdc.gov/cdc-info/index.html>  
(800)-232-4636





**Thank you!**